Boston Scientific Initiates $2 Billion Accelerated Share Repurchase Program
BSX is trading near its 52-week low of $52.52 (2.0% above the low).
Summary
Boston Scientific has commenced a $2 billion Accelerated Share Repurchase (ASR) program, utilizing a portion of its existing $5 billion authorization, with final settlement expected by June 30, 2026.
Key Events · Financing and Capital Events · BSX
-
$2 Billion Accelerated Share Repurchase (ASR)
Boston Scientific has entered into an ASR agreement for $2 billion of its common stock, part of its previously announced $5 billion share repurchase authorization.
-
Significant Share Count Reduction
The ASR is expected to repurchase approximately 30.4 million shares based on the May 15, 2026 closing price of $52.68, with the final number determined by the volume-weighted average price during the term.
-
EPS Accretion Expected
The ASR is projected to be $0.02 accretive to adjusted earnings per share for full year 2026, improving upon previously issued guidance.
-
Remaining Buyback Authorization
Following the completion of this ASR, Boston Scientific will have $3 billion remaining under its current share repurchase authorization.
Analysis · BSX · Industrial Applications And Services
Boston Scientific is executing a significant portion of its previously authorized share repurchase program by launching a $2 billion Accelerated Share Repurchase (ASR). This move, representing a substantial capital allocation, is particularly notable as the company's stock is trading near its 52-week low. The ASR is expected to be accretive to adjusted EPS, signaling management's confidence in the company's valuation and commitment to returning value to shareholders.
At the time of this filing, BSX was trading at $53.55 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $78.3B. The 52-week trading range was $52.52 to $109.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.